ArticleBiomaterials research2026
Multifunctional Biomaterial Strategies to Regulate Inflammation and Promote Kidney Repair.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) involves inflammation, fibrosis, and impaired regeneration. We developed a biofunctional hybrid scaffold (PMEAR/MM/uEV) combining a porous poly(lactic-co-glycolic acid)-porcine extracellular matrix, ricinoleic acid-modified magnesium hydroxide, metanephric mesenchyme-like cells, and ureteric bud-derived extracellular vesicles, with resveratrol and adapalene to confer antioxidant and pro-regenerative properties. The scaffold exhibited uniform porosity, pH-buffering, and reactive oxygen species-scavenging activity. In vitro, it accelerated epithelial wound closure, reduced oxidative stress, and shifted cytokine profiles toward an anti-inflammatory state by increasing interleukin-4 while decreasing tumor necrosis factor-alpha, interleukin-6, and interleukin-8. In a 5/6 nephrectomy mouse model, PMEAR/MM/uEV reduced collagen deposition, improved blood urea nitrogen and creatinine, and up-regulated podocyte markers synaptopodin, nephrin, and podocin, as well as the renal developmental marker Pax2. mRNA sequencing revealed activation of angiogenesis, extracellular matrix remodeling, oxidative defense, and immune modulation, with Kyoto Encyclopedia of Genes and Genomes enrichment in tumor necrosis factor and interleukin-17 signaling and nuclear factor kappa B-associated pathways. These findings establish PMEAR/MM/uEV as an effective, multimodal platform for kidney regeneration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.